Monographie - Asparaginase - Stabilis 4.0

Last update :
19/11/2024

Anticancer drug

Asparaginase

injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Elspar	Mexico, United States of America
Kidrolase	Argentina, Bulgaria, Canada, Chile, Colombia, Ecuador, Egypt, Israel, Morocco, Saudi Arabia, Turkey
L Aspase	India
Laspar	Republic of South Africa
Leunase	Australia, Japan, Malaysia, Mexico
Paronal	Belgium, Italy, Netherlands
Spectrila	France

References

injection

References : Asparaginase

	Type	Publication
150	Journal	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
1858	Journal	Stecher AL, Morgantetti de Deus P, Polikarpov I, Abrahao-Neto J. Stability of L-asparaginase: an enzyme used in leukemia treatment. Pharm Acta Helv 1999 ; 74: 1-9.
2148	Journal	Lanvers C, Pinheiro JPV, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002 ; 309: 117-126.
3128	Manufacturer	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3243	Poster	Nicolson O, d'Hayer B, Vieillard V, Dollet S, Astier A, Paul M. Stability of diluted L-asparaginase in normal saline solution. ECCO Congress Stockholm 2011
3686	Manufacturer	L asparaginase (Kidrolase®) - Résumé des caractéristiques du produit Eusapharma 2013
4471	Manufacturer	Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019

Mentions Légales